Wayne A Border
Physician in Salt Lake City, UT
License number
Utah 169498-8905
Issued Date
Jun 15, 1983
Expiration Date
Jan 31, 2018
Category
Physician
Type
Physician/Surgeon CS (Schedule 2-5)
Address
Address
Salt Lake City, UT
Personal information
See more information about Wayne A Border at radaris.comName
Address
Phone
Teasdale, UT
4454 Abinadi Rd, Salt Lake City, UT 84124
4464 Abinadi Rd, Holladay, UT 84124
524 Purple Lilac Ln, Sandy, UT 84070
556 Purple Lilac Ln, Sandy, UT 84070
Organization information
See more information about Wayne A Border at bizstanding.comWayne Border MD
391 Chipeta Way, Salt Lake City, UT 84108
Industry:
Internist
Phone:
(801) 364-0370 (Phone)
Wayne Allen Border
Professional information
See more information about Wayne A Border at trustoria.com
Dr. Wayne A Border - MD (Doctor of Medicine)
Dr. Wayne A Border - MD (Doctor of Medicine)
Hospitals:
50 N Medical Dr, Salt Lake City 84132
University of Utah Health Care
50 North Medical Dr, Salt Lake City 84132
50 N Medical Dr, Salt Lake City 84132
University of Utah Health Care
50 North Medical Dr, Salt Lake City 84132
University of Utah Health Care
50 North Medical Dr, Salt Lake City 84132
50 N Medical Dr, Salt Lake City 84132
University of Utah Health Care
50 North Medical Dr, Salt Lake City 84132
Education:
Medical Schools
Washington University St Louis
Graduated: 1968
Washington University St Louis
Graduated: 1968
Methods Of Decreasing The Accumulation Of Extracellular Matrix Associated With Glomerulonephritis With Anti-Tgf-Β-Specific Antibodies
Methods Of Decreasing The Accumulation Of Extracellular Matrix Associated With Glomerulonephritis With Anti-Tgf-Β-Specific Antibodies
US Patent:
7214375, May 8, 2007
Filed:
Dec 2, 1994
Appl. No.:
08/349479
Inventors:
Wayne A. Border - Salt Lake City UT, US
Erkki I. Ruoslahti - Ranco Santa Fe CA, US
Erkki I. Ruoslahti - Ranco Santa Fe CA, US
Assignee:
La Jolla Cancer Research Foundation - La Jolla CA
International Classification:
A61K 39/395, C07K 16/24
US Classification:
4241451, 4241301, 4241411, 4241581, 5303871, 5303881, 5303882, 53038823
Abstract:
The present invention provides a method for treating or arresting the progress of pathologies characterized by an accumulation of extracellular matrix components by providing an agent to suppress the activity of transforming growth factor β (TGF-β) a peptide growth factor which is anabolic and leads to fibrosis and angiogenesis. In one embodiment, such agent is anti-TGF-β antibody. Pathologies which can be so treated include, but are not limited to, glomerulonephritis, adult respiratory distress syndrome and cirrhosis of the liver. The invention further provides a method for the diagnosis of pathologies, or incipient pathologies, which are characterized by the accumulation of extracellular matrix components in tissues by determining the levels of TGF-β in the tissues, a high level being indicative of such pathologies.
Methods Of Preventing Or Reducing Scarring With Decorin Or Biglycan
Methods Of Preventing Or Reducing Scarring With Decorin Or Biglycan
US Patent:
6509314, Jan 21, 2003
Filed:
Jun 13, 1994
Appl. No.:
08/259335
Inventors:
Erkki I. Ruoslahti - Rancho Santa Fe CA
Wayne A. Border - Salt Lake City UT
Wayne A. Border - Salt Lake City UT
Assignee:
The Burnham Institute - La Jolla CA
International Classification:
A01N 6100
US Classification:
514 8, 514 2, 530350
Abstract:
The present invention relates to methods of preventing or reducing scarring in a wound area by administering decorin or biglycan to the wound.
Methods For Treating Conditions Associated With The Accumulation Of Excess Extracellular Matrix
Methods For Treating Conditions Associated With The Accumulation Of Excess Extracellular Matrix
US Patent:
7763580, Jul 27, 2010
Filed:
Sep 27, 2004
Appl. No.:
10/952361
Inventors:
Nancy A. Noble - Salt Lake City UT, US
Wayne A. Border - Salt Lake City UT, US
Wayne A. Border - Salt Lake City UT, US
Assignee:
University of Utah Research Foundation - Salt Lake City UT
International Classification:
A61K 38/14, A61K 38/55, A61K 31/4164, A61K 31/401, C12Q 1/68
US Classification:
514 2, 514 4, 514 44 A, 435 6, 435375, 435 4, 435 71
Abstract:
The present invention is methods and compositions for reducing and preventing the excess accumulation of extracellular matrix in a tissue and/or organ or at a wound site using a combination of agents that inhibit TGFβ, or using agents that inhibit TGFβ in combination with agents that degrade excess accumulated extracellular matrix, or at least one agent that degrades excess accumulated extracellular matrix. The compositions and methods of the invention are used to treat conditions such as fibrotic diseases and scarring that result from excess accumulation of extracellular matrix, impairing tissue or organ function or skin appearance in a subject.
Anti-Transforming Growth Factor-.Beta. Gene Therapy
Anti-Transforming Growth Factor-.Beta. Gene Therapy
US Patent:
5824655, Oct 20, 1998
Filed:
Feb 15, 1995
Appl. No.:
8/389887
Inventors:
Wayne A. Border - Salt Lake City UT
Assignee:
The University of Utah - Salt Lake City UT
International Classification:
A01N 4304
US Classification:
514 44
Abstract:
The present invention provides methods for reducing a pathology in a subject characterized by a deleterious accumulation of TGF-. beta. -induced extracellular matrix in a tissue by introducing a nucleic acid encoding a TGF. beta. -specific inhibitory agent or active fragment thereof into a cell in the subject. In one embodiment, the nucleic acid encoding the TGF-. beta. specific inhibitory agent is introduced into a cell in vivo by injection, for example, in skeletal muscle. In another embodiment, the nucleic acid encoding the TGF-. beta. specific inhibitory agent is transfected into a cell ex vivo to obtain a cell expressing the agent, and the cell is then administered into the subject to be treated. TGF-. beta. specific inhibitory agents of the present invention include, but are not limited to, members of the decoring family of proteoglycans such as decorin, biglycan, fibromodulin and lumican or an antibody specific for TGF-. beta. Pathologies that can be reduced by the present invention include various fibrotic diseases and conditions.
Methods For Preventing And Treating Fibrotic Diseases Resulting From Accumulation Of Excess Extracellular Matrix Induced By Tgf.beta. Using Renin Inhibitors
Methods For Preventing And Treating Fibrotic Diseases Resulting From Accumulation Of Excess Extracellular Matrix Induced By Tgf.beta. Using Renin Inhibitors
US Patent:
6316258, Nov 13, 2001
Filed:
Dec 15, 1998
Appl. No.:
9/211916
Inventors:
Nancy A. Noble - Salt Lake City UT
Wayne A. Border - Salt Lake City UT
Wayne A. Border - Salt Lake City UT
Assignee:
University of Utah - Salt Lake City UT
International Classification:
G01N 3350
US Classification:
435375
Abstract:
The present invention is methods for inhibiting the renin-induced production of TGF. beta. using a renin inhibitory agent to reduce excess accumulation of extracellular matrix in tissue in a subject, and to the use of renin inhibitory agents and additional TGF. beta. inhibitory agents to reduce TGF. beta. production to treat and prevent fibrotic diseases.
Methods For Treating Conditions Associated With The Accumulation Of Excess Extracellular Matrix
Methods For Treating Conditions Associated With The Accumulation Of Excess Extracellular Matrix
US Patent:
2008017, Jul 24, 2008
Filed:
Oct 30, 2007
Appl. No.:
11/981283
Inventors:
Nancy A. Noble - Salt Lake City UT, US
Wayne A. Border - Salt Lake City UT, US
Wayne A. Border - Salt Lake City UT, US
Assignee:
University of Utah Research Foundation - Salt Lake City UT
International Classification:
A61K 48/00, A61K 31/473, A61K 31/403, A61K 31/401, A61K 39/395
US Classification:
4241461, 514412, 514423, 514 44, 514290
Abstract:
The present invention is methods and compositions for reducing and preventing the excess accumulation of extracellular matrix in a tissue and/or organ or at a wound site using a combination of agents that inhibit TGFβ, or using agents that inhibit TGFβ in combination with agents that degrade excess accumulated extracellular matrix, or at least one agent that degrades excess accumulated extracellular matrix. The compositions and methods of the invention are used to treat conditions such as fibrotic diseases and scarring that result from excess accumulation of extracellular matrix, impairing tissue or organ function or skin appearance in a subject.
Methods For Treating Conditions Associated With The Accumulation Of Excess Extracellular Matrix
Methods For Treating Conditions Associated With The Accumulation Of Excess Extracellular Matrix
US Patent:
7713924, May 11, 2010
Filed:
Jul 8, 2004
Appl. No.:
10/887378
Inventors:
Nancy A. Noble - Salt Lake City UT, US
Wayne A. Border - Salt Lake City UT, US
Daniel A. Lawrence - Derwood MD, US
Wayne A. Border - Salt Lake City UT, US
Daniel A. Lawrence - Derwood MD, US
Assignee:
University of Utah Research Foundation - Salt Lake City UT
The American National Red Cross - Rockville MD
The American National Red Cross - Rockville MD
International Classification:
A61K 38/14, A61K 38/55, A61K 31/401, C12Q 1/68
US Classification:
514 2, 514 4, 514 44, 435 4, 435 6, 435 71
Abstract:
The present invention is methods and compositions for reducing and preventing the excess accumulation of extracellular matrix in a tissue and/or organ or at a wound site using a combination of agents that inhibit TGFβ, or using agents that inhibit TGFβ in combination with agents that degrade excess accumulated extracellular matrix. The compositions and methods of the invention are used to treat conditions such as fibrotic diseases and scarring that result from excess accumulation of extracellular matrix, impairing tissue or organ function or skin appearance in a subject.
Methods For Treating Conditions Associated With The Accumulation Of Excess Extracellular Matrix
Methods For Treating Conditions Associated With The Accumulation Of Excess Extracellular Matrix
US Patent:
6906026, Jun 14, 2005
Filed:
Jul 5, 2000
Appl. No.:
09/869820
Inventors:
Nancy A. Noble - Salt Lake City UT, US
Wayne A. Border - Salt Lake City UT, US
Wayne A. Border - Salt Lake City UT, US
Assignee:
The University of Research Foundation - Salt Lake City UT
International Classification:
A61K048/00, A61K039/395, A61K038/00
US Classification:
514 2, 514 4, 514 44, 435 4, 435 6, 435 71
Abstract:
The present invention is methods and compositions for reducing and preventing the excess accumulation of extracellular matrix in a tissue and/or organ or at a wound site using a combination of agents that inhibit TGFβ, or using agents that inhibit TGFβ in combination with agents that degrade excess accumulated extracellular matrix. The compositions and methods of the invention are used to treat conditions such as fibrotic diseases and scarring that result from excess accumulation of extracellular matrix, impairing tissue or organ function or skin appearance in a subject.
Treatment Of Glomerulonephritis With Decorin
Treatment Of Glomerulonephritis With Decorin
US Patent:
5726149, Mar 10, 1998
Filed:
Jan 22, 1991
Appl. No.:
7/645339
Inventors:
Erkki I. Ruoslahti - Rancho Santa Fe CA
Yu Yamaguchi - San Diego CA
Wayne A. Border - Salt Lake City UT
Yu Yamaguchi - San Diego CA
Wayne A. Border - Salt Lake City UT
Assignee:
La Jolla Cancer Research Foundation - La Jolla CA
International Classification:
A61K 3802, A61K 3816, A61K 3839
US Classification:
514 8
Abstract:
A method of treating of glomerulonephritis in a patient by administering decorin.